Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study

Protocol No
ECOG-EA6194
Principal Investigator
Amy Harker-Murray
Phase
II
Summary
This study is being done to answer the following question: Will treatment before surgery with either pembrolizumab alone, or pembrolizumab combined with CMP-001, cause your melanoma to shrink enough that no more living tumor cells are evident at the time of surgery. This study will also try to answer whether these forms of immunotherapy can affect the chances of the melanoma returning (“relapse risk”) and the chances of death from melanoma (“survival”). We are doing this study because we want to find out if this approach is better or worse than the usual approach for your skin cancer. The usual approach is defined as care most people get for melanoma.
Description
Pembrolizumab Alone or With CMP-001 in Operable Melanoma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category